Bicara Therapeutics Inc. (BCAX)
NASDAQ: BCAX · Real-Time Price · USD
21.87
+0.26 (1.20%)
Apr 9, 2026, 12:46 PM EDT - Market open
Company Description
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors.
Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors.
The company was incorporated in 2018 and is based in Boston, Massachusetts.
Bicara Therapeutics Inc.
| Country | United States |
| Founded | 2018 |
| IPO Date | Sep 13, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 103 |
| CEO | Claire Mazumdar Clemon |
Contact Details
Address: 116 Huntington Avenue, Suite 703 Boston, Massachusetts 02116 United States | |
| Phone | 617 468 4219 |
| Website | bicara.com |
Stock Details
| Ticker Symbol | BCAX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $18.00 |
| CIK Code | 2023658 |
| CUSIP Number | 055477103 |
| ISIN Number | US0554771032 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Claire Mazumdar Clemon M.B.A., Ph.D. | Chief Executive Officer and Director |
| Ryan Cohlhepp Pharm.D. | President, Chief Operating Officer and Director |
| Ivan Hyep M.B.A. | Chief Financial Officer |
| Lara S. Meisner J.D. | Chief Legal Officer and Corporate Secretary |
| Pauline Dufresne | Chief People Officer |
| Rachel Salazar | SVice President of Research & Development Strategy and Operations |
| Sathish Hasige Ph.D. | Senior Vice President and Head of Technical Operations and Supply Chain |
| Dr. David Raben M.D. | Chief Medical Officer |
| Angela Windt | Vice President and Head of Regulatory Affairs |
| Dr. Jeltje Schulten M.B.A., M.D. | Senior Vice President of Clinical and Medical Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 8, 2026 | SCHEDULE 13G/A | Filing |
| Mar 31, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 30, 2026 | 10-K | Annual Report |
| Mar 30, 2026 | 8-K | Current Report |
| Mar 25, 2026 | 144 | Filing |
| Mar 23, 2026 | 144 | Filing |
| Mar 20, 2026 | 144 | Filing |
| Mar 19, 2026 | 144 | Filing |
| Mar 18, 2026 | 144 | Filing |
| Mar 16, 2026 | 144 | Filing |